BIRC5 and ovarian carcinoma: Although the data alone may not necessarily eliminate the possibility that domatinostat exerted its growth-inhibitory and chemosensitizing effects also through other mechanisms independent of survivin, our results suggest that the ability of domatinostat to target the FOXM1–survivin axis underlies its anti-cancer activities in ovarian cancer cells.